Shanghai Pharmaceuticals Holding (2607.HK) Earnings Analysis
Shanghai Pharmaceuticals Holding (2607.HK) next reports earnings on 2026-08-27, consensus EPS 0.4441 HKD. Last quarter (2026-04-29) it beat with EPS 0.4318 HKD vs 0.4012 HKD est (+7.6%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E 10.57.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 2607.HK next report earnings?
| Next earnings date | 2026-08-27 |
|---|---|
| Consensus EPS estimate | 0.4441 HKD |
| Revenue estimate | 81.67B |
2607.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-29 | 0.4318 HKD | 0.4012 HKD | +7.6% | Beat |
| 2026-03-26 | 0.1781 HKD | 0.217 HKD | -17.9% | Miss |
| 2025-10-30 | 0.2077 HKD | 0.3061 HKD | -32.1% | Miss |
| 2025-08-28 | 0.924 HKD | 0.91 HKD | +1.5% | Beat |
| 2024-08-26 | 0.37 HKD | 0.33 HKD | +12.1% | Beat |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
2607.HK valuation and analyst view
| Trailing P/E | 10.57 |
|---|---|
| Trailing EPS | 1.567 HKD |
| Price / book | 0.80 |
| Dividend yield | 3.86% |
| Market cap | 68.97B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Shanghai Pharmaceuticals Holding (2607.HK)'s next earnings date?
Shanghai Pharmaceuticals Holding is next scheduled to report on 2026-08-27, with a consensus EPS estimate of 0.4441 HKD and revenue estimate of 81.67B.
Did 2607.HK beat earnings last quarter?
In its 2026-04-29 report, 2607.HK posted EPS of 0.4318 HKD versus a 0.4012 HKD estimate — a beat of 7.6%.
What is 2607.HK's earnings track record?
Over the last 5 reported quarters with consensus data, 2607.HK beat estimates 3 times (60%).
What is 2607.HK's current P/E ratio and EPS?
2607.HK trades at a trailing P/E of 10.57 on trailing EPS of 1.566525630992875 HKD.
What do analysts rate 2607.HK?
2607.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.